From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

brentuximab vedotin   Click here for help

GtoPdb Ligand ID: 6772

Synonyms: Adcetris® | anti-CD30 ADC SGN-35 | SGN 35
Approved drug Immunopharmacology Ligand
brentuximab vedotin is an approved drug (FDA (2011), EMA (2012))
Compound class: Antibody
Comment: Antibody-drug conjugate (ADC) that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). The PubChem ID for the MMAE component compound is CID 11542188. The invention of this ADC is claimed in patent US7090843 [4] and the original article describing the parent antibody (C10 or AC10) is [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Immunopharmacology Comments
Brentuximab vedotin is an ADC targeting CD-30 positive tumour cells.
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic scleroderma Disease Ontology: DOID:418
OMIM: 181750
Orphanet: ORPHA90291
 Phase 1/2 clinical candidate for systemic sclerosis- see NCT03222492 and NCT03198689
Mastocytosis Disease Ontology: DOID:350
 Phase 2 clinical candidate for aggressive systemic mastocytosis, mast cell leukemia and systemic mastocytosis- see NCT01807598
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
 Ex Phase 2 clinical candidate for adults with SLE- trial NCT02533570 was terminated
Mycosis fungoides OMIM: 254400
Orphanet: ORPHA2584
 Approved drug for CD-30 positive MF. 3
Anaplastic large cell lymphoma Disease Ontology: DOID:0050744
 Approved drug for systemic anaplastic large cell lymphoma, and primary cutaneous ALCL.
Lymphoma, Hodgkin, Classic; CHL Disease Ontology: DOID:8567
OMIM: 236000
 Approved drug for HL.